Brachytherapy With Durvalumab (MEDI4736) and Tremelimumab in Subjects With Platinum-Resistant or Refractory and Recurrent or Metastatic Gynecological Malignancies

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 19 Jul 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
Indications Cervical cancer; Endometrial cancer; Gynaecological cancer; Ovarian cancer
Focus Adverse reactions; Therapeutic Use

12 Jul 2024 Planned End Date changed from 1 Dec 2025 to 1 Dec 2026.
12 Jul 2024 Planned primary completion date changed from 1 Dec 2024 to 1 Dec 2025.
25 Jun 2024 Planned End Date changed from 1 Jun 2025 to 1 Dec 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com